Pediatrics, Rheumatology

• 

  People

  • Administrative Positions

    • Rabinovich, Consuelo Egla Diana, Chief, Division of Pediatric Rheumatology

  • Primary Appointments

    • Ardalan, Kaveh, Assistant Professor of Pediatrics
    • Balevic, Stephen Joseph, Assistant Professor of Pediatrics
    • Becker, Mara, Associate Professor of Pediatrics
    • Dvergsten, Jeffrey Arthur, Associate Professor of Pediatrics
    • Rabinovich, Consuelo Egla Diana, Professor of Pediatrics
    • Schanberg, Laura Eve, Professor of Pediatrics
    • Van Mater, Heather Ann, Associate Professor of Pediatrics
    • Wu, Eveline, Adjunct Assistant Professor in the Department of Pediatrics

  • Secondary Appointments

    • Sadun, Rebecca Eli, Assistant Professor in Pediatrics
• 

  Administers Grant

  • A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNF¿ Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
  • A Randomized, Open Label, Multi-Center Phas 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular JIA (Limit-JIA)
  • A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of 2 dose levels of subcutaneious anakinra in patients with Still's disease
  • ACR/Amgen Rheumatology Fellowship Training Award
  • ACR/Amgen Rheumatology Fellowship Training Award
  • ACR/Amgen Rheumatology Fellowship Training Award
  • ACR/Amgen Rheumatology Fellowship Training Award
  • Adverse Childhood Experiences in Juvenile Idiopathic Arthritis
  • An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extensi
  • An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b
  • CARRA
  • CARRA Early Investigator Chair Support
  • CARRA Early Investigator Vice Chair Support
  • CARRA Registry Continuation
  • Electronic Diary Assessment of Pain in Juvenile Arthritis
  • Enhancing Clinical Meaningfulness and Usefulness of PROMIS Pediatric Measures Via Validation in Children and Adolescents with Rheumatic Disease, Cancer of Inflammatory Bowel Disease
  • Identifying Pharmacogenomic Predictors of Methotrexate Response and Metabolite Biotransformation in JIA
  • Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients with Polyarticular-Course adn Systemic Juvenile Idiopathic Arthritis
  • Mental Health Screening in Juvenile Myositis: Pilot and Feasibility Study
  • Metabolomic Analysis of Paired Serum and Skeletal Muscle in Juvenile Inflammatory Myositis Compared to Controls
  • New CARRA Registry
  • PULSE: Pediatric Update on Lupus in South Africa: Epidemiology & Management
  • Pediatric Rheumatology Research Annual Scientific Meeting
  • Pediatrics JuvenileMyositis program support
  • Precision Decision in the Treatment of Juvenile Dermatomyositis
  • Precision Decision in the Treatment of the Juvenile idiopathic Inflammatory Myopathies
  • RRF Medical and Graduate Student Preceptorship
  • Regulation Of The T Cell Specific Gene Cd7
  • Regulation Of The T-Cell Specific Gene Cd7
  • Stress, Mood & Disease Activity In Juvenile Rheumatoid Art
  • Urinary HER2 as a biomarker for lupus nephritis
  • WA28117: Tocilizumab in Polyarticular-Course JIA
  • WA28118: Tocilizumab in Systemic JIA
  • WebSMART Trial-Year 4

Add data to my Website